Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1989-10-23
1993-05-18
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514 19, 514423, A61K 3700, A61K 3166, A61K 3140
Patent
active
052121658
ABSTRACT:
A method is provided for rehabilitating or restoring the vasorelaxant action of the endothelium impaired by atherosclerosis and/or hypercholesterolemia, thereby preventing arteriospasm in the coronary arteries using an angiotensin converting enzyme inhibitor such as captopril, fosinopril, ceranapril, enalapril or lisinopril, which may be administered by oral or parenteral dosage forms.
REFERENCES:
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo
patent: 4374829 (1983-02-01), Harris et al.
patent: 4452790 (1984-06-01), Karanewsky et al.
Andrews, P., et al, "Reversal of Experimental Acute Cerebral Vasospasm by Angiotensin Converting Enzyme Inhibition", Stroke, vol. 13, No. 4, Jul.-Aug. 1982, pp. 480-483.
Gavras, H., et al, "Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition", J. Neurosurg. 5:884-888, (1981).
Miyazaki, S., et al, "Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon," Brit. Med. J., vol. 284, 30 Jan. (1982).
Trubestein, G., et al, "Treatment of Raynaud's phenomenon with captopril", DMW 1984, 109 Jg., Nov. 22, pp. 857-860.
Rustin, M., et al, "The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon", Brit. J. of Dermatology (1987) 117, pp. 751-758.
Tosi, S., et al, "Treatment of Raynaud's Phenomenon with Captopril", Drugs Exptl. Clin. Res. XIII(1) 37-42 (1987).
Rustin, M., et al, "Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin", Brit. J. of Dermatology (1989) 120, 101-105.
Coffman, J., "Symptomatic Therapy for Raynaud's Phenomenon", Drug Therapy/Jun. 1989, pp. 95-104.
Madsen, J., et al, "Raynaud's sygdom behandlet med kaptopril (Capoten)", Ugeskr Laeger 146;2695-2697 (1984).
Hartich, L. P., et al, "Effects of antihypertensive agents on vascular responses," Kidney Int. 35:326, (1989).
Shultz, P., et al, "Effect of oral administration of antihypertensive agents on endothelium dependent and endothelium independent vascular relaxation," J. Am. Coll. Cardiol. 13:83A, (1989).
de Nucci, G., et al, "Effect of captopril on the bradykinin-induced release of prostacyclin from guinea pig lungs and bovine aortic endothelial cells," Br. J. Pharmacol., 95(3), 783-8, Nov. 1988.
Schoelkens, B., et al, "Local Inhibition of Angiotensin II Formation and Bradykinin Degradation in Isolated Hearts," Clin. Exp. Hypertens. A (10, No. 6, 1259-70, 1988).
van Gilst, W. H., et al, "The Coronary Vasodilatory Mechanism of SH-Containing Converting Enzyme Inhibitors: Potentiation of Endogenous Nitrate," Circulation (78, No. 4, Pt 2, 221, 1988).
Thuermann, P., et al, "Anti-Ischemic Efficacy of Enalapril in Patients with Coronary Heart Disease. A Randomized Placebo-Controlled Double-blind Study (Ger.)," Klin. Wochenschr (66, Suppl. 13, 87, 1988).
Luscher, T. F., et al, "Antihypertensive Treatment Normalizes Decreased Endothelium-Dependent Relaxations in Salt-Induced Hypertension of the Rat," Circulation (74, No. 4, Pt. 2, 286, 1986).
de Nucci, G., et al, "Pressor Effects of Circulating Endothelin are Limited by its Removal in the Pulmonary Circulation and by the release of Prostacyclin and Endothelium-Derived Relaxing Factor," Proc. Natl. Acad. Sci. U.S.A. (85, No. 24, 9797-800, 1988).
The Merck Manual, Fourteenth Ed., 1982, p. 558.
Aberg A. K. Gunnar
Ondetti Miguel A.
E. R. Squibb & Sons Inc.
Jordan Kimberly R.
Rodney Burton
Waddell Frederick E.
LandOfFree
Method for rehabilitating the vasorelaxant action of the coronar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for rehabilitating the vasorelaxant action of the coronar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for rehabilitating the vasorelaxant action of the coronar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-804583